T细胞白血病相关的核糖体RPL10 R98S突变增强JAK-STAT信号传导
研究探讨了T细胞急性淋巴细胞白血病中复发性核糖体蛋白L10 R98S突变的致病机制。蛋白组筛选及转基因小鼠和异种移植样本证实RPL10 R98S细胞中JAK-STAT信号蛋白过表达,细胞因子刺激后JAK-STAT通路过度激活,对临床JAK-STAT抑制剂更敏感。患者中RPL10 R98S与JAK-STAT突变互斥,提示功能模拟;RPL10 R98S还降低程序性核糖体移码和Jak1降解,并降低蛋白酶体活性、增强对蛋白酶体抑制剂的敏感性。
要点
- RPL10 R98S突变在T-ALL中导致JAK-STAT信号通路过度激活。
- RPL10 R98S与JAK-STAT突变在T-ALL患者中互斥,提示功能模拟。
- RPL10 R98S细胞对JAK-STAT抑制剂和蛋白酶体抑制剂敏感性增强。
核心结论
- 核糖体突变RPL10 R98S通过调节JAK-STAT级联发挥促癌活性,扩展了该级联在白血病中的相关性。
研究设计与样本
- 研究使用工程化RPL10 R98S小鼠淋巴样细胞、转基因Rpl10 R98S小鼠造血细胞和T-ALL异种移植样本进行蛋白组筛选及功能验证。
主要发现
- 蛋白组筛选显示工程化RPL10 R98S小鼠淋巴样细胞中多种Jak-Stat信号蛋白过表达,并在转基因Rpl10 R98S小鼠造血细胞和T-ALL异种移植样本中确认。
- RPL10 R98S表达细胞在细胞因子刺激下显示JAK-STAT通路过度激活,且对临床使用的JAK-STAT抑制剂如匹莫齐特敏感性增加。
- T-ALL患者中RPL10 R98S与JAK-STAT突变呈互斥模式,提示RPL10 R98S功能上模拟JAK-STAT激活。
- 机制上,RPL10 R98S除引起转录变化外,还导致小鼠和人类Jak-Stat基因中多个核糖体移码信号处表观程序性核糖体移码减少,以及Jak1降解减少。
- RPL10 R98S细胞显示蛋白酶体活性降低,并对临床蛋白酶体抑制剂敏感性增强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several somatic ribosome defects have recently been discovered in cancer, yet their oncogenic mechanisms remain poorly understood. Here we investigated the pathogenic role of the recurrent R98S mutation in ribosomal protein L10 (RPL10 R98S) found in T-cell acute lymphoblastic leukemia (T-ALL). The JAK-STAT signaling pathway is a critical controller of cellular proliferation and survival. A proteome screen revealed overexpression of several Jak-Stat signaling proteins in engineered RPL10 R98S mouse lymphoid cells, which we confirmed in hematopoietic cells from transgenic Rpl10 R98S mice and T-ALL xenograft samples. RPL10 R98S expressing cells displayed JAK-STAT pathway hyper-activation upon cytokine stimulation, as well as increased sensitivity to clinically used JAK-STAT inhibitors like pimozide. A mutually exclusive mutation pattern between RPL10 R98S and JAK-STAT mutations in T-ALL patients further suggests that RPL10 R98S functionally mimics JAK-STAT activation. Mechanistically, besides transcriptional changes, RPL10 R98S caused reduction of apparent programmed ribosomal frameshifting at several ribosomal frameshift signals in mouse and human Jak-Stat genes, as well as decreased Jak1 degradation. Of further medical interest, RPL10 R98S cells showed reduced proteasome activity and enhanced sensitivity to clinical proteasome inhibitors. Collectively, we describe modulation of the JAK-STAT cascade as a novel cancer-promoting activity of a ribosomal mutation, and expand the relevance of this cascade in leukemia.
引用
- Girardi T, Vereecke S, Sulima SO, et al. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. Leukemia. 2017. PMID: 28744013. doi:10.1038/leu.2017.225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。